Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

Conditions

• Long Term Follow up Dry Eye Disease

Interventions

• DRUG: OC-01 Low Dose, 0.12 mg/mL
• DRUG: OC-01 Mid Dose, 0.6 mg/mL
• DRUG: OC-01 High Dose, 1.2 mg/mL
• DRUG: Placebo (vehicle) nasal spray

Sponsor

Oyster Point Pharma, Inc.